NCT01635764View on ClinicalTrials.gov

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa

PHASE3CompletedINTERVENTIONAL

Enrollment

508

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Hidradenitis Suppurativa

Interventions

BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

All Listed Sponsors

lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01635764 - Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter